L. Lebel

发表

Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation

Brian T. O’Neill, Yi Lu, Huang Jianhua, 2005 .

Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase.

J. Lowe, D. Helweg, J. Chen, 1991, Journal of medicinal chemistry.

In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine.

F. Tingley, H. Rollema, B. O’Neill, 2005, Bioorganic & medicinal chemistry letters.

3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.

F. Tingley, H. Rollema, B. O’Neill, 2005, Bioorganic & medicinal chemistry letters.

In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisine

F. Tingley, H. Rollema, B. O’Neill, 2005 .

Effects of novel catechol ether imidazolidinones on calcium‐independent phosphodiesterase activity, [3H]rolipram binding, and reserpine‐induced hypothermia in mice

I. Williams, N. Saccomano, B. Koe, 1990 .

Synthesis and SAR studies of 1,4-diazabicyclo[3.2.2]nonane phenyl carbamates--subtype selective, high affinity alpha7 nicotinic acetylcholine receptor agonists.

R. J. Mather, C. J. O’Donnell, Frank M Nedza, 2009, Bioorganic & medicinal chemistry letters.

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

F. Tingley, J. Heym, H. Rollema, 2005, Journal of medicinal chemistry.

Sertraline potently displaces (+)-[3H]3-PPP binding to σ sites in rat brain

Anne W. Schmidt, J. Heym, T. Seeger, 1989 .

Dopamine uptake inhibitory activity of novel tryptamine 5‐HT1 receptor ligands

J. Macor, L. Lebel, C. Fox, 1994 .

[3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter.

J. Lowe, C. Strick, L. Lebel, 2003, Bioorganic & medicinal chemistry letters.

4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.

R. G. Browne, P. Seymour, R. Sarges, 1990, Journal of medicinal chemistry.

3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.

J. Macor, K. Ryan, J. Heym, 1990, Journal of medicinal chemistry.

Deconstructing cytisine: The syntheses of (+/-)-cyfusine and (+/-)-cyclopropylcyfusine, fused ring analogs of cytisine.

D. Yohannes, B. O’Neill, L. Lebel, 2008, Bioorganic & medicinal chemistry letters.

4‐Amino(1,2,4)triazolo(4,3‐a)quinoxalines. A Novel Class of Potent Adenosine Receptor Antagonists and Potential Rapid‐Onset Antidepressants.

R. G. Browne, P. Seymour, R. Sarges, 1991 .

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.

K. Fennell, J. Pandit, F. Menniti, 2011, Journal of medicinal chemistry.

1-(2-Aminoethyl)-3-methyl-8,9-dihydropyrano[3,2-e]indole: a rotationally restricted phenolic analog of the neurotransmitter serotonin and agonist selective for serotonin (5-HT2-type) receptors.

J. Macor, S. Zorn, B. Koe, 1992, Journal of medicinal chemistry.

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Anne W. Schmidt, J. Lowe, P. Seymour, 1995, The Journal of pharmacology and experimental therapeutics.

Enhancement of benzodiazepine binding by methaqualone and related quinazolinones

B. Koe, L. Lebel, S. Koch, 1986 .

Small-molecule phosphodiesterase probes: discovery of potent and selective CNS-penetrable quinazoline inhibitors of PDE1

M. Mansour, J. Pandit, F. Menniti, 2014 .

Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.

Spiros Liras, Meihua Tu, J. Pandit, 2007, Journal of medicinal chemistry.

Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis

F. Menniti, J. Siuciak, C. J. Schmidt, 2006, Neuropharmacology.

3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation

F. Tingley, H. Rollema, B. O’Neill, 2005 .

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

R. J. Mather, R. Hurst, F. Tingley, 2007, Neuropharmacology.

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

R. Hurst, F. Tingley, Y. Lu, 2007, Neuropharmacology.

Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.

Anne W. Schmidt, S. Zorn, H. Howard, 2001, European journal of pharmacology.

5-[(3-nitropyrid-2-yl)amino]indoles: novel serotonin agonists with selectivity for the 5-HT1D receptor. Variation of the C3 substituent on the indole template leads to increased 5-HT1D receptor selectivity.

Anne W. Schmidt, J. Macor, K. Ryan, 1994, Journal of medicinal chemistry.

Sertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of beta-adrenoceptor system of rat brain.

B. Koe, L. Lebel, M. G. Page, 1987, European journal of pharmacology.

(+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)-piperidine binding to σ receptors in mouse brain in vivo

B. Koe, L. Lebel, C. A. Burkhart, 1989 .

Sertraline potently displaces (+)-[3H]3-PPP binding to sigma sites in rat brain.

J. Heym, T. Seeger, B. Koe, 1989, European journal of pharmacology.

5-cyano-1-[3-(N-methylpyrrolidin-2R-ylmethyl)indol-5-yl] benzimidazole (CP-161,242): A potent, centrally active 5-HT1D receptor agonist and benzodiazepine partial agonist

Anne W. Schmidt, P. Seymour, J. Macor, 1995 .

Contrasting effects of ethyl beta-carboline-3-carboxylate (beta CCE) and diazepam on cerebellar cyclic GMP content and antagonism of both effects by Ro 15-1788, a specific benzodiazepine receptor blocker.

B. Koe, L. Lebel, 1983, European journal of pharmacology.

The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter.

J. Lowe, Xinjun Hou, L. Lebel, 2009, Bioorganic & medicinal chemistry letters.

A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening.

J. Lowe, M. Peakman, C. Strick, 2007, Bioorganic & Medicinal Chemistry Letters.

Characterization of [3H]CP‐96,501 as a Selective Radioligand for the Serotonin 5‐HT1B Receptor: Binding Studies in Rat Brain Membranes

J. Macor, B. Koe, L. Lebel, 1992, Journal of neurochemistry.

Binding and uptake studies with [3H]CP‐93, 129, a radiolabeled selective 5‐HT1B receptor ligand

J. Macor, B. Koe, L. Lebel, 1992 .

CP-93,129: A Potent and Selective Agonist for the Serotonin (5-HT1B) Receptor and Rotationally Restricted Analog of RU-24,969

K. Ryan, J. Heym, B. Koe, 1991 .

3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one: A Potent and Selective Serotonin (5-HT1B) Agonist and Rotationally Restricted Phenolic Analogue of 5-Methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.

K. Ryan, J. Heym, B. Koe, 1991 .

Binding studies with the 5‐HT1B receptor agonist [3H]CP‐96,501 in brain tissues

L. Lebel, B. Kenneth Koe, 1992 .

[3H] sertraline binding to rat brain membranes

W. M. Welch, B. Koe, L. Lebel, 2005, Psychopharmacology.

Biochemical evidence for a new benzodiazepine receptor antagonist

L. Lebel, K. Minor, Elena Kondratas, 1985 .

Calcium-Independent Phosphodiesterase Inhibitors as Putative Antidepressants: (3-(Bicycloalkoxy)-4-methoxyphenyl)-2- imidazolidinones.

D. Helweg, N. Saccomano, D. Phillips, 1991 .

Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation

J. Heym, H. Rollema, B. O’Neill, 2005 .

Synthesis of 5‐(2,3‐ditritiopropoxy)‐3‐(1,2,5,6‐tetrahydropyrid‐4‐yl)indole ([3H]CP‐96,501): A selective ligand for the serotonin (5‐HT1B) receptor

B. Koe, L. Lebel, R. Roth, 1991 .

Effects of serotoninergic agents on downregulation of beta-adrenoceptors by the selective serotonin reuptake inhibitor sertraline.

B. Koe, L. Lebel, 1995, Archives internationales de pharmacodynamie et de therapie.